Finance

Lists
ABVX:EPA
Abivax SA
၈၃.၅၀ €
-၀.၇၇%
(-၀.၆၅) 1D
အောက် ၂, GMT+၂ ၁၇:၃၅:၂၃  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
၈၃.၆၅ €
High
၈၅.၂၀ €
Low
၈၂.၈၀ €
Mkt. cap
၇၁၉.၆၁ ဋေ
Avg. vol.
၁.၅၅ သိန်း
Volume
၁.၂၀ သိန်း
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
Open
၈၃.၆၅ €
High
၈၅.၂၀ €
Low
၈၂.၈၀ €
Mkt. cap
၇၁၉.၆၁ ဋေ
Avg. vol.
၁.၅၅ သိန်း
Volume
၁.၂၀ သိန်း
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၁ နာရီ
Phase 2 Trial Plans Could Be A Game Changer For Absci Stock (ABSI)
Yahoo Finance
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ နာရီ
Forget the S&P 500: SCHD Is Beating It by Nearly 10 Points in 2026 and Its Dividend Just Grew
FXLeaders
FXLeaders
·
ပြီးခဲ့သည့် ၁၂ မိနစ်
Dow Jones and Nasdaq Futures Open Higher as Buyers Target New Records
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees၉၈
Founded၂၀၁၃ ဒီ ၄
Headquarters-
Sector-
Websiteabivax.com
Last report
၂၀၂၆ စက် ၂၁
Fiscal period
Q2 2026
EPS / Est. (EUR)
- / -၀.၆၁ €
Revenue / Est. (EUR)
၉.၇၆ သိန်း / ၈.၁၅ သိန်း
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၆.၃၉ သိန်း
၁.၉၁ သန်း
၁.၃၄ သန်း
၉.၇၆ သိန်း
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
၅.၅၄ ကုဋေ
၄.၄၄ ကုဋေ
၄.၉၅ ကုဋေ
၅.၈၃ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၂.၇၃ ကုဋေ
၂.၇၇ ကုဋေ
၈.၀၃ သန်း
၂.၇၀ ကုဋေ
Operating expense
၈.၁၄ ကုဋေ
၇.၃၆ ကုဋေ
၅.၇၆ ကုဋေ
၈.၅၁ ကုဋေ
Total operating expenses
၈.၁၄ ကုဋေ
၇.၃၆ ကုဋေ
၅.၇၆ ကုဋေ
၈.၅၁ ကုဋေ
Operating income
-၈.၀၇ ကုဋေ
-၇.၁၆ ကုဋေ
-၅.၆၂ ကုဋေ
-၈.၄၁ ကုဋေ
Other non operating income
-၇.၄၂ ကုဋေ
-၄.၉၆ သန်း
၁.၁၉ သိန်း
၄.၇၂ သန်း
EBT including unusual items
-၁၅.၃၄ ကုဋေ
-၇.၆၁ ကုဋေ
-၄.၈၂ ကုဋေ
-၁၂.၃၅ ကုဋေ
EBT excluding unusual items
-၁၅.၃၄ ကုဋေ
-၈.၀၈ ကုဋေ
-၅.၁၅ ကုဋေ
-၈.၀၃ ကုဋေ
Income tax expense
-
၅.၈၅ သန်း
၂.၂၈ သိန်း
-၆.၀၈ သန်း
Effective tax rate
-
-၇.၆၈%
-၀.၄၇%
၄.၉၂%
Other operating expenses
-၁.၄၀ သန်း
၁.၄၇ သန်း
-
-၂.၂၅ သိန်း
Net income
-၁၅.၃၄ ကုဋေ
-၈.၂၀ ကုဋေ
-၄.၈၅ ကုဋေ
-၁၁.၇၄ ကုဋေ
Net profit margin
-၂၃,၉၉၉.၆၉%
-၄,၂၈၂.၁၃%
-၃,၆၀၆.၂၅%
-၁၂,၀၃၂.၀၇%
Earnings per share
-
-
-
-
Interest and investment income
၃.၃၆ သန်း
၁.၁၉ သန်း
၆.၄၄ သိန်း
-
Interest expense
-၄.၂၁ သန်း
-၁.၅၃ ကုဋေ
-၂.၅၄ သန်း
-၇.၃၀ သိန်း
Net interest expenses
-၈.၅၂ သိန်း
-၁.၄၁ ကုဋေ
-၁.၉၀ သန်း
-၇.၃၀ သိန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၈.၀၆ ကုဋေ
-၇.၀၈ ကုဋေ
-၅.၆၁ ကုဋေ
-၈.၄၀ ကုဋေ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google အက်ပ်များ